Daily Endocrinology Research Analysis
Analyzed 32 papers and selected 3 impactful papers.
Summary
A randomized clinical trial showed that pelacarsen markedly reduced reliance on lipoprotein(a) apheresis and lowered Lp(a) by 72% in secondary prevention. A mechanistic study in gestational diabetes delineated an EMP-mediated NGF–NGFR–CYLD–MAPK/ERK pathway driving placental overgrowth and identified coenzyme Q10 as a targeted modulator. Preclinical work revealed lycorine directly targets ILF3 to rebalance Nrf2/NF-κB signaling and ameliorate diabetic cardiomyopathy.
Research Themes
- Lipoprotein(a)-targeted therapeutics and apheresis sparing
- Placental pathophysiology in gestational diabetes via extracellular vesicle signaling
- Inflammation modulation in diabetic cardiomyopathy through ILF3–Nrf2/NF-κB crosstalk
Selected Articles
1. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial.
In a 52-week randomized trial of 51 patients with elevated Lp(a) and established CVD, pelacarsen reduced normalized apheresis session rates (0.16 vs 0.93; OR 0.006) and decreased Lp(a) by 72% versus placebo. Time to sustained apheresis avoidance shortened markedly (HR 88.3; median 6.1 weeks), with similar overall adverse events aside from mild injection-site erythema.
Impact: Demonstrates apheresis-sparing efficacy of a targeted Lp(a) therapy with robust effect sizes over 52 weeks, addressing a key unmet need in secondary prevention.
Clinical Implications: Pelacarsen could substantially reduce or eliminate routine apheresis in selected patients with high Lp(a) and CVD, easing procedural burden while achieving profound Lp(a) lowering; outcomes trials will clarify effects on major adverse cardiovascular events.
Key Findings
- Normalized apheresis session rate: 0.16 with pelacarsen vs 0.93 with placebo (OR 0.006; 95% CI 0.003–0.013; P<.0001).
- Placebo-adjusted Lp(a) change at week 52: −72% (95% CI −79% to −61%; P<.0001).
- Markedly increased hazard of sustained apheresis avoidance (HR 88.3; P=0.0014; median 6.1 weeks) with similar overall AEs, aside from mild injection-site erythema.
Methodological Strengths
- Randomized, placebo-controlled, 52-week parallel-group design with clear, operational endpoints.
- ClinicalTrials.gov-registered (NCT05305664) with high completion rates and balanced baseline characteristics.
Limitations
- Modest sample size (n=51) and single-country (Germany) setting may limit generalizability.
- Endpoints focused on apheresis utilization and Lp(a) reduction rather than hard cardiovascular outcomes.
Future Directions: Conduct adequately powered, multinational outcomes trials to assess effects on MACE and evaluate long-term safety, cost-effectiveness, and quality-of-life impacts of apheresis avoidance.
BACKGROUND AND AIMS: Lipoprotein apheresis (LA) is the only approved treatment for patients with elevated lipoprotein(a) [Lp(a)]. The Lp(a)FRONTIERS APHERESIS trial investigated whether pelacarsen reduces the need for LA in patients from Germany with elevated Lp(a) and established cardiovascular disease (CVD). METHODS: Adult patients with Lp(a) levels >60 mg/dl who had undergone ≥35 LA sessions in the prior year were randomized to receive pelacarsen 80 mg or placebo every 4 weeks for 52 weeks. Weekly LA sessions were performed if the Lp(a) measurement from the prior visit was >60 mg/dL. The primary endpoint was the rate of performed LA sessions normalized to the weekly LA schedule (the number of actual LA sessions divided by the number of planned LA sessions during the 52-week period). Secondary endpoints were time to LA avoidance (for ≥24 consecutive weeks) and total LA avoidance from week 12 to week 52. RESULTS: Fifty-one patients were randomized (mean age 61.7 years, mean Lp(a) at baseline 85.4 mg/dL, and mean 44.0 LA sessions in the past 12 months), with 25 of 26 (96.2%) in the pelacarsen arm and 23 of 25 (92.0%) in the placebo arm completing the study. Baseline characteristics were generally balanced between treatment arms. Pelacarsen reduced the mean rates of LA (0.16 vs 0.93 in placebo, odds ratio 0.006, 95% confidence interval [CI] 0.003, 0.013; P < .0001) and substantially increased the hazard of achieving LA avoidance (hazard ratio: 88.3; P = .0014; median time to achieve LA avoidance: 6.1 weeks) and total LA avoidance (odds ratio: 163.2; P = .0005). The placebo-adjusted Lp(a) change from baseline at week 52 was -72% (95% CI: -79%, -61%; P < .0001). Treatment emergent adverse events were similar between arms, except for mostly mild injection site erythema (pelacarsen 38.5%; placebo 0%). CONCLUSIONS: Pelacarsen is a highly effective and well-tolerated Lp(a)-targeted therapy that substantially reduces the need for LA in patients with elevated Lp(a) and established CVD. CLINICALTRIALS.GOV, IDENTIFIER: NCT05305664.
2. Endothelial microparticles in high glucose environment: molecular pathways of GDM-associated placental dysfunction and coenzyme Q10-based targeted therapy.
GDM patients exhibit elevated circulating EMPs that enhance trophoblast migration/invasion. Hyperglycemia drives KLF9-dependent NGF packaging into EMPs, which stabilizes trophoblastic NGFR via CYLD and activates MAPK/ERK signaling to promote placental overgrowth. Coenzyme Q10 disrupts NGFR–CYLD, restores NGFR degradation, and attenuates this pathological signaling.
Impact: Reveals a previously uncharacterized EMP–NGF–NGFR–CYLD axis linking maternal hyperglycemia to placental overgrowth and nominates coenzyme Q10 as a safe, mechanistically targeted modulator.
Clinical Implications: EMP levels and NGF–NGFR signaling components may serve as mechanistic biomarkers in GDM; coenzyme Q10, already used in pregnancy for other indications, warrants clinical testing as an adjunct to glycemic control to mitigate placental overgrowth.
Key Findings
- Circulating EMPs were significantly higher in GDM patients than in healthy pregnant controls and promoted trophoblast migration/invasion.
- Hyperglycemia activated KLF9 in endothelial cells, upregulating NGF, which was packaged into EMPs and stabilized trophoblastic NGFR via CYLD, activating MAPK/ERK signaling.
- Coenzyme Q10 bound NGFR, disrupted NGFR–CYLD interaction, restored NGFR ubiquitin–proteasome degradation, and reduced pathological signaling induced by GDM-derived EMPs.
Methodological Strengths
- Integration of clinical observation with mechanistic dissection across molecular, cellular, and signaling levels.
- Target validation using binding assays and pathway-specific functional rescue with a safe, readily translatable molecule (coenzyme Q10).
Limitations
- Lack of randomized interventional human data; in vivo validation in pregnancy models was not detailed in the abstract.
- Generalizability of findings and optimal dosing/regimen of coenzyme Q10 require clinical studies.
Future Directions: Prospective studies to validate EMP/NGF–NGFR biomarkers and dose-finding randomized trials of coenzyme Q10 as an adjunct therapy in GDM to prevent placental overgrowth and related complications.
Gestational diabetes mellitus (GDM) is frequently linked to placental overgrowth and hypertrophy, while maternal hyperglycaemic environment consistently induces systemic vascular endothelial cell injury. Damaged endothelial cells stimulate the release of endothelial microparticles (EMPs), but their impact on placental function has not been fully characterized. In this study, we clinically observed that the levels of EMPs in the peripheral blood of GDM patients are significantly higher than those in healthy pregnant women. Furthermore, we identified that EMPs from GDM patients promote excessive trophoblast migration and invasion. Mechanistically, hyperglycemia activates KLF9 in endothelial cells, leading to transcriptional upregulation of NGF. When encapsulated within EMPs, NGF binds to NGFR on placental trophoblast membranes and promotes NGFR interaction with CYLD, which inhibited NGFR ubiquitination and degradation. This interaction activated the downstream MAPK/ERK signalling pathway, facilitating excessive trophoblast migration and invasion and ultimately resulting in placental overgrowth. Notably, by screening natural molecules safe for gestational intake, we identified coenzyme Q10, which directly targets and binds to NGFR to eliminate the interaction between NGFR and CYLD, thereby promoting NGFR degradation via the ubiquitin‒proteasome pathway and reducing pathological NGFR accumulation caused by G-EMPs exposure. Our findings illuminate the intricate relationship between vascular endothelial cell injury and placental developmental abnormalities and identifying potential therapeutic targets and drugs to improve outcomes for affected patients.
3. Lycorine improves inflammatory imbalance in diabetic cardiomyopathy by targeting ILF3.
In vitro and STZ-diabetic mouse models, lycorine significantly reduced cardiac inflammation and injury. Target deconvolution identified ILF3 as a direct binding partner, enabling lycorine to enhance Nrf2-mediated anti-inflammatory signaling and suppress NF-κB, restoring inflammatory homeostasis.
Impact: Identifies ILF3 as a tractable inflammatory hub in diabetic cardiomyopathy and demonstrates direct small-molecule engagement with multi-modal validation, opening a novel therapeutic avenue.
Clinical Implications: While preclinical, these data support ILF3 as a therapeutic target for diabetic cardiovascular complications and justify medicinal chemistry optimization and early-phase clinical translation of lycorine-derived compounds.
Key Findings
- Lycorine attenuated cardiac inflammation and injury in high glucose/palmitate-treated cardiomyocytes and STZ-diabetic mice.
- Target identification demonstrated direct binding of lycorine to ILF3 (validated by SPR and CETSA), modulating Nrf2 and NF-κB pathways.
- ILF3 knockdown phenocopied lycorine’s protective effects, indicating ILF3 activity is required for efficacy.
Methodological Strengths
- Convergent target validation with LC-MS/MS, molecular docking, SPR, CETSA, and RNAi across in vitro and in vivo models.
- Mechanistic linkage from target engagement to pathway modulation and phenotypic rescue.
Limitations
- Preclinical study without human data; dosing, pharmacokinetics, and safety profiles in humans remain unknown.
- Disease heterogeneity and comorbidities in human DCM may affect translatability of ILF3 targeting.
Future Directions: Advance structure–activity optimization of lycorine analogs, perform target-engagement biomarkers development, and initiate phased toxicology and first-in-human studies in cardiometabolic populations.
BACKGROUND: Diabetic cardiomyopathy (DCM) is characterized by chronic low-grade inflammation and metabolic disturbances, leading to progressive cardiac dysfunction. Lycorine (LY), a complex tetracyclic pyrrolo[de]phenanthridine alkaloid from the Amaryllidaceae family, has shown potential anti-inflammatory effects, but its role in DCM pathogenesis remains unexplored. PURPOSE: This study investigated the cardioprotective effect of LY in DCM and its underlying molecular mechanisms. METHODS: We employed both in vitro (high glucose/palmitic acid-treated cardiomyocytes) and in vivo (streptozotocin-induced diabetic mice) models to investigate LY's cardioprotective effects. Liquid chromatography-tandem mass spectrometry, molecular docking, surface plasmon resonance binding assay, cellular thermal shift assay, and RNA interference approaches were utilized to identify the key target and mechanistic pathways. RESULTS: In vitro and in vivo models of DCM revealed that LY significantly attenuated cardiac inflammation. Mechanistically, liquid chromatography-tandem mass spectrometry analysis revealed that LY targeted interleukin enhancer-binding factor 3 (ILF3), a critical regulator of inflammatory responses. Notably, surface plasmon resonance and cellular thermal shift assay data validated a direct interaction between LY and ILF3. By interacting with ILF3, LY enhanced nuclear factor erythroid 2-related factor 2-mediated anti-inflammatory responses while suppressing NF-κB-driven pro-inflammatory signaling, thereby restoring inflammatory homeostasis and reducing myocardial injury. Furthermore, ILF3 knockdown mimicked the protective effects of LY, and ILF3 activity was essential for LY's cardioprotective effects. CONCLUSION: These findings suggest that LY ameliorates DCM by modulating ILF3-dependent nuclear factor erythroid 2-related factor 2 and NF-κB crosstalk to restore inflammatory balance, suggesting its potential as a novel therapeutic agent for diabetic cardiovascular complications.